产品
编 号：F464903
分子式：C48H82O18
分子量：947.15
分子式：C48H82O18
分子量：947.15
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 80321-69-3
产品详情
生物活性：
Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate estrogen receptors.
体内研究：
Body weights are measured as physical measures of hormone bioactivity. Mean body weights are significantly higher in every group compared to that of the control, but there is no significant difference in body weight between the different treatments during the 10-week feeding. The mouse plasma lipid levels are also measured at the end of 10 weeks of a high-fat diet. Circulating levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are significantly increased in the treated groups of ApoE-/- mice compared with those of the C57BL/6J control group; Gypenoside XVII (GP-17) and Probucol treatment substantially decreases both of these parameters relative to those of the ApoE-/- model group.
体外研究：
The ability of Gypenoside XVII (GP-17) to prevent Ox-LDL-induced cytotoxicity is detected by cell viability assays. Gypenoside XVII does not demonstrate any cytotoxicity in HUVECs.Gypenoside XVII can protect HUVECs against Ox-LDL-induced apoptosis.Gypenoside XVII dose-dependently mitigates the toxic effect of Ox-LDL on HUVEC viability.The viability of HUVECs is significantly higher than that of other groups at 50 μg/mL Gypenoside XVII .
Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate estrogen receptors.
体内研究：
Body weights are measured as physical measures of hormone bioactivity. Mean body weights are significantly higher in every group compared to that of the control, but there is no significant difference in body weight between the different treatments during the 10-week feeding. The mouse plasma lipid levels are also measured at the end of 10 weeks of a high-fat diet. Circulating levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are significantly increased in the treated groups of ApoE-/- mice compared with those of the C57BL/6J control group; Gypenoside XVII (GP-17) and Probucol treatment substantially decreases both of these parameters relative to those of the ApoE-/- model group.
体外研究：
The ability of Gypenoside XVII (GP-17) to prevent Ox-LDL-induced cytotoxicity is detected by cell viability assays. Gypenoside XVII does not demonstrate any cytotoxicity in HUVECs.Gypenoside XVII can protect HUVECs against Ox-LDL-induced apoptosis.Gypenoside XVII dose-dependently mitigates the toxic effect of Ox-LDL on HUVEC viability.The viability of HUVECs is significantly higher than that of other groups at 50 μg/mL Gypenoside XVII .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备